Immunomedics
This article was originally published in The Gray Sheet
Executive Summary
Receives nonapprovable letter from FDA for a product license application for the company's ImmuRAID-CEA colorectal cancer imaging agent. The Morris Plains, New Jersey firm plans to meet with the agency "promptly" to discuss issues raised in the letter and remains confident the product "ultimately" will be licensed